StockTipsArenaBeta

SELL Mankind Pharma Limited — Macquarie

SELLMankind Pharma Limited
Mankind Pharma share price target & all analyst calls

byMacquarieHorizon: NA (inferred 1 year)31 Jul 2026via CNBC Awaaz.

Entry₹2,604Inferred
Target₹2,080
Total upside +20.12%
Stop lossNot given
CMP₹2,212.62d ago
Active+15.03%+5.99%upside left 9 mo left
Follow Macquarie for new calls(100% target hit, 14 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 6 other Long-term calls on MANKINDSee 274 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 11:51 pm IST
2 supporting14 neutral24 opposing
Supports the SELL call (2)

Mankind Pharma auditor resigns as subsidiary Bharat Serums enters liquidation

NewsGoogle News·28 Sept · 4w ago

(opens in new tab)

Mankind Pharma's subsidiary Bharat Serums and Vaccines sees auditor resignation amid liquidation

NewsGoogle News·28 Sept · 4w ago

(opens in new tab)
Neutral / worth noting (14)

Q2 FY27 results scheduled — board meets 26 Oct 2026

BSE · Board Meeting·26 Oct · today

(opens in new tab)

Mankind Pharma To Give Rs 1 Crore To Flydubai Captain Smit Machchhar, Family For Averting Flight Disaster

NewsNdtv-Profit·3 Oct · 3w ago

(opens in new tab)
Weighs against the SELL call (24)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·23 Oct · 2d ago

Mankind Pharma to acquire a majority stake in Armed Cell Therapeutics to enter the CAR-T therapy market.

BSE · Company Update·15 Oct · 1w ago

(opens in new tab)

Mankind Pharma will acquire a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. for EUR 48 million to expand into next-generation CAR-T cancer therapies.

NSE · Acquisition·15 Oct · 1w ago

(opens in new tab)

Mankind Pharma will acquire a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. for EUR 48 million to expand into next-generation CAR-T cancer therapies.

BSE · Company Update·15 Oct · 1w ago

(opens in new tab)

Mankind Pharma will acquire a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. for EUR 48 million to expand into next-generation CAR-T cancer therapies.

NSE · Outcome of Board Meeting·15 Oct · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Mankind Pharma

All analyst calls on Mankind Pharma

More from Macquarie

Every call and its outcome